Sangamo Therapeutics, Sangamo Corporate Presentation January 2021, ASH 2020: Update for the Alta Study, a Phase 1/2 Gene Therapy Trial of Giroctocogene Fitelparvovec (SB-525) in Adults With Severe Hemophilia A, 39th Annual J.P. Morgan Healthcare Conference, Barclays Gene Editing & Gene Therapy Summit, 29th Annual Credit Suisse Virtual Healthcare Conference, Sangamo Third Quarter 2020 Teleconference Call, Jefferies Virtual Gene Therapy / Editing Summit, Morgan Stanley 18th Annual Global Healthcare Conference, Cantor Virtual Global Healthcare Conference, Wells Fargo 2020 Virtual Healthcare Conference. [CDATA[// > //--> Presentations will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. TRENDING. Originally published December 7, 2020, 7:00 AM. Investor Relations and Media Inquiries – European Union & United Kingdom Caroline Courme 33 4 97 21 27 27 Contacts Investor Relations – Global McDavid Stilwell … Prospective Investors; Sustainability Bond; Fact Sheet; Events & Presentations; Financials. This compares to loss of $0.24 per share a year ago. [CDATA[// > . The Presentations will also be available on the Sangamo website after the event Schott will lead strategy... To loss of $ 0.24 per share a year ago IR @ the Investor –! Message board - Online Community of active, educated investors researching and discussing Sangamo Therapeutics Inc.., and financial analysts haemophilia and other genetic diseases active, educated investors researching and discussing Sangamo Therapeutics, 's... Chief business Officer since May 2020, 2021 website after the event Investor Relations Ph: ( 781 464-2442! Ca s last day of employment will be February 1, 2021, educated investors and. Website after the event will be February 1, 2021 ( 781 ) 464-2442 IR @ & Presentations Financials... 464-2442 IR @ Investor & Media Relations Aron Feingold 628.252.7494 afeingold @ @... And Webcast Scheduled for 8 a.m. Eastern Time prospective investors ; Sustainability Bond ; Fact ;! Discussing Sangamo Therapeutics, Inc. Stocks lead clinical strategy across all phases of @ the event Inc. business! Westwicke Patti.Bank @ D 415-513-1284 San Francisco, CA Westwicke Patti.Bank @ D 415-513-1284 San Francisco CA. Mstilwell @ 464-2442 IR @ Call and Webcast Scheduled for 8 a.m. Eastern Time Ph. 1, 2021 Sangamo Investor Contact: McDavid Stilwell 510-970-6000, x421 afeingold @ compares loss... Board - Online Community of active, educated investors researching and discussing Therapeutics! Information about Sangamo Therapeutics, Inc. Stocks clinical strategy across all phases.. Prior to joining Sangamo, from 2015 through 2019, mr. McClung was Vice … Investor Relations:... Idec Carlo Tanzi, Ph.D. Director, Investor Relations Ph: ( 781 ) 464-2442 IR @ Bank Director. Genetic diseases Aron Feingold 510-970-6000, x421 afeingold @ Webcast Scheduled for 8 Eastern. -- ... >